Previous studies found that mutations in B-Raf or N-Ras in melanoma confer chemoresistance to MEK inhibitors by switching the metabolic mode to OXPHOS through upregulating PGC-1α or TFAM (transcription factor A, mitochondrial) to meet their bioenergy requirements [91, 93]. This evidence concerns the gene PPARGC1A and melanoma.